Valuation
- Market cap
- 4,924,000
- Revenue TTM
- $0
- Net income TTM
- $-5,580,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 6,045,600
- Avg volume
- 2,357,130
- Day's range
- $0.69 – $0.90
- Shares out
- 5,862,000
- Stochastic %K
- 85%
- Beta
- 0.33
- Analysts
- Hold
- Price target
- $26.00
Company profile
Salarius Pharmaceuticals, Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugat...
Show more
Salarius Pharmaceuticals, Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugates targeting various unmet medical needs. The company focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. Salarius Pharmaceuticals, Inc. is based in Houston, Texas.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 713 913 5608
- Website
- https://www.salariuspharma.com
- Address
- 2450 Holcombe Blvd., Suite X, Houston, United States
Latest news
No headlines yet.
